Identification

Name
Tapentadol
Accession Number
DB06204
Type
Small Molecule
Groups
Approved
Description

Opioid analgesic for treatment of moderate to severe pain. FDA approved on Nov 20, 2008.

Structure
Thumb
Synonyms
  • Tapentadol
External IDs
BN 200 / BN-200 / CG-5503 / CG5503 / CG5503 IR / R331333
Product Ingredients
IngredientUNIICASInChI Key
Tapentadol hydrochloride71204KII53175591-09-0ZELFLGGRLLOERW-YECZQDJWSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NucyntaTablet, film coated50 mg/1OralPhysicians Total Care, Inc.2010-03-19Not applicableUs
NucyntaTablet, film coated100 mg/1OralJanssen Pharmaceuticals, Inc.2009-06-012020-03-31Us
NucyntaTablet, film coated100 mg/1Oralbryant ranch prepack2009-06-012014-06-01Us
NucyntaTablet, film coated75 mg/1OralDepo Nf Sub, Llc2017-06-16Not applicableUs
NucyntaTablet50 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2010-09-29Not applicableUs
NucyntaTablet, film coated50 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2018-04-20Not applicableUs
NucyntaTablet, film coated100 mg/1OralPhysicians Total Care, Inc.2010-03-19Not applicableUs
NucyntaTablet, film coated50 mg/1OralJanssen Pharmaceuticals, Inc.2009-06-012020-03-31Us
NucyntaTablet, film coated100 mg/1OralStat Rx USA2009-06-01Not applicableUs
NucyntaSolution20 mg/1mLOralJanssen Pharmaceuticals2012-10-152018-10-31Us
International/Other Brands
Nucynta / Palexia (Grünenthal Ltd) / TAPAL (MSN Labs )
Categories
UNII
H8A007M585
CAS number
175591-23-8
Weight
Average: 221.3385
Monoisotopic: 221.177964363
Chemical Formula
C14H23NO
InChI Key
KWTWDQCKEHXFFR-SMDDNHRTSA-N
InChI
InChI=1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1
IUPAC Name
3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol
SMILES
CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1

Pharmacology

Indication

The immediate-release formulation of tapentadol is indicated for the relief of moderate to severe acute pain. The long-acting formulation serves as a continuous, around-the-clock analgesic that is indicated for the relief of moderate to severe chronic pain or neuropathic pain associated with diabetic peripheral neuropathy.

Associated Conditions
Pharmacodynamics

Tapentadol is a centrally-acting synthetic analgesic. It is 18 times less potent than morphine in terms of binding to human mu-opioid receptors. It also increases norepinephrine concentrations in the brains of rats via inhibition of norepinephrine reuptake. Selective mu-opioid antagonists like naloxone can block analgesia from tapentadol. It also has not effect on the QT interval.

Mechanism of action

Tapendadol causes large increases in levels of extracellular norepinephrine (NE) due to a dual mechanism of action involving mu opioid receptor (MOR) agonism as well as noradrenaline reuptake inhibition.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
ASodium-dependent noradrenaline transporter
inhibitor
Human
UKappa-type opioid receptorNot AvailableHuman
UDelta-type opioid receptorNot AvailableHuman
U5-hydroxytryptamine receptor 3ANot AvailableHuman
USodium-dependent serotonin transporter
inhibitor
Human
Absorption

Bioavailability, immediate release (IR), 86 mg: 32%; Bioavailability, extended release (ER), 86 mg: 32%; Cmax, IR: 64.2 ng/mL; Cmax, ER: 22.5 ng/mL; T max, IR: 1.5 hours; T max, ER: 5.0 hours; Tapentadol accumulates following multiple repeat doses.

Volume of distribution

Following IV administration, volume of distribution is 540 ± 98 L.

Protein binding

~20%

Metabolism

97% of the dose is metabolized mostly via conjugation with glucuronic acid to produce glucuronides. Tapentadol is also metabolized into N-desmethyl tapentadol (13%) by CYP2C9 and CYP 2C19. CYP2D6 is involved in the formation of the metabolite, hydroxy tapentadol (2%). All metabolites are inactive.

Route of elimination

Tapentadol and its metabolites are excreted almost exclusively (99%) via the kidneys. Approximately 70% (55% O-glucuronide and 15% sulfate of tapentadol) is excreted in conjugated form. A total of 3% of drug was excreted in urine as unchanged drug.

Half life

Elimination half-life, IV: 4 hours.

Clearance

Total clearance = 1530 ± 177 ml/min.

Toxicity

Oral, rabbit: LD50 = 3200 mg/kg; Oral, mouse: LD50 = 300 mg/kg; Oral, rat: LD50: 980 mg/kg; The most common reasons for discontinuation due to adverse events were dizziness, nausea, vomiting, somnolence, and headache.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of adverse effects can be increased when Tapentadol is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of adverse effects can be increased when Tapentadol is combined with (S)-Warfarin.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of serotonin syndrome can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Tapentadol.
2,5-Dimethoxy-4-ethylthioamphetamineTapentadol may increase the central nervous system depressant (CNS depressant) activities of 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineTapentadol may increase the central nervous system depressant (CNS depressant) activities of 3,4-Methylenedioxyamphetamine.
4-Bromo-2,5-dimethoxyamphetamineTapentadol may increase the central nervous system depressant (CNS depressant) activities of 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarinThe risk or severity of adverse effects can be increased when Tapentadol is combined with 4-hydroxycoumarin.
4-MethoxyamphetamineTapentadol may increase the central nervous system depressant (CNS depressant) activities of 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamineTapentadol may increase the central nervous system depressant (CNS depressant) activities of 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleTapentadol may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.
Food Interactions
  • Food increases the AUC and Cmax of tapentadol. Despite this, tapentadol can be given without regards to food.

References

Synthesis Reference

Giuseppe Motta, Domenico Vergani, Giorgio Bertolini, "PROCESS FOR THE PREPARATION OF TAPENTADOL AND INTERMEDIATES THEREOF." U.S. Patent US20120232306, issued September 13, 2012.

US20120232306
General References
  1. Tzschentke TM, Christoph T, Kogel B, Schiene K, Hennies HH, Englberger W, Haurand M, Jahnel U, Cremers TI, Friderichs E, De Vry J: (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007 Oct;323(1):265-76. Epub 2007 Jul 26. [PubMed:17656655]
  2. Gohler K, Brett M, Smit JW, Rengelshausen J, Terlinden R: Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. Int J Clin Pharmacol Ther. 2013 Apr;51(4):338-48. doi: 10.5414/CP201722. [PubMed:23357834]
  3. Xu XS, Smit JW, Lin R, Stuyckens K, Terlinden R, Nandy P: Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain. Clin Pharmacokinet. 2010 Oct;49(10):671-82. doi: 10.2165/11535390-000000000-00000. [PubMed:20818833]
External Links
KEGG Drug
D06007
PubChem Compound
9838022
PubChem Substance
175427057
ChemSpider
8013742
BindingDB
50386381
ChEBI
135935
ChEMBL
CHEMBL1201776
PharmGKB
PA166179720
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Tapentadol
ATC Codes
N02AX06 — Tapentadol
AHFS Codes
  • 28:08.08 — Opiate Agonists
FDA label
Download (666 KB)
MSDS
Download (481 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers1
1TerminatedTreatmentAllodynia / Hyperalgesia / Pain NOS1
1, 2CompletedBasic ScienceOpioid Induced Motor Disturbances1
2CompletedTreatmentBack Pain Lower Back1
2CompletedTreatmentBack Pain / Back Pain Lower Back / Knee Osteoarthritis (Knee OA) / Pain NOS1
2CompletedTreatmentBunions / Pain NOS1
2CompletedTreatmentDiabetic Neuropathies / Neurocostal neuralgia / Pain NOS / Postherpetic Neuralgia1
2CompletedTreatmentPain, Acute / Postoperative pain1
2CompletedTreatmentPostoperative pain1
2TerminatedTreatmentModerate to Severe Acute Post-operative Pain / Moderate to Severe Acute Postoperative Pain1
2, 3Active Not RecruitingTreatmentPain NOS1
3CompletedTreatmentArthritis / Joint Diseases / Osteoarthritis (OA)1
3CompletedTreatmentBack Pain1
3CompletedTreatmentBack Pain Lower Back2
3CompletedTreatmentBack Pain Lower Back / Knee Osteoarthritis (Knee OA) / Osteoarthritis, Hip / Pain NOS1
3CompletedTreatmentBack Pain Lower Back / Osteoarthritis (OA) / Pain NOS1
3CompletedTreatmentBack Pain Lower Back / Pain, Chronic1
3CompletedTreatmentBack Pain / Back Pain Lower Back / Back Pain With Radiation / Pain NOS1
3CompletedTreatmentBunionectomy / Pain NOS / Pain, Acute / Postoperative pain1
3CompletedTreatmentArthralgia/joint pain / Bunions / Hallux Valgus / Pain NOS1
3CompletedTreatmentDiabetic Neuropathies1
3CompletedTreatmentDiabetic Peripheral Neuropathy (DPN)1
3CompletedTreatmentHallux Valgus2
3CompletedTreatmentHysterectomy / Postoperative1
3CompletedTreatmentKnee Osteoarthritis (Knee OA) / Pain NOS2
3CompletedTreatmentNeoplasms1
3CompletedTreatmentOsteoarthritis (OA) / Pain, Chronic1
3CompletedTreatmentPain NOS1
3CompletedTreatmentPain NOS / Tumors1
3CompletedTreatmentPostoperative pain1
3RecruitingTreatmentJoint Diseases1
3SuspendedTreatmentPain, Acute1
3TerminatedTreatmentArthroplasty1
3TerminatedTreatmentDiabetic Neuropathy, Painful / Diabetic Polyneuropathy1
3TerminatedTreatmentMalignancies / Neoplasms / Pain NOS / Tumors1
3TerminatedTreatmentMalignancies / Pain NOS / Pain, Chronic1
3TerminatedTreatmentOsteoarthritis (OA) / Pain, Chronic1
4CompletedSupportive CareEffects of 2 Mu-opiates on Gastrointestinal Transit1
4CompletedTreatmentBack Pain / Back Pain Lower Back / Pain, Neuropathic1
4Not Yet RecruitingPreventionKnee Osteoarthritis (Knee OA)1
4RecruitingTreatmentAnalgesics, Antipyretics, and Antirheumatics Causing Adverse Effects in Therapeutic Use / Opioids Use / Pain Uterus / Pain, Acute / Postoperative pain / Visceral Pain1
4TerminatedNot AvailablePeripheral Neuropathy1
4WithdrawnNot AvailableModerate to Severe Acute Non-Cancer Pain1
4WithdrawnTreatmentBack Pain Lower Back Chronic / Chronic Back Pain / Osteoarthritis Pain In The Hip or Knee / Pain NOS1
Not AvailableCompletedNot AvailableBreakthrough Cancer Pain / Pain, Cancer / Pain, Neuropathic / Tumors1
Not AvailableCompletedNot AvailableSubstance Abuse Detection1
Not AvailableCompletedTreatmentAnalgesia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionOral20 mg/1mL
TabletOral50 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coatedOral75 mg/1
Tablet, extended releaseOral100 mg
Tablet, extended releaseOral150 mg
Tablet, extended releaseOral200 mg
Tablet, extended releaseOral250 mg
Tablet, extended releaseOral50 mg
Tablet, film coated, extended releaseOral100 mg/1
Tablet, film coated, extended releaseOral150 mg/1
Tablet, film coated, extended releaseOral200 mg/1
Tablet, film coated, extended releaseOral250 mg/1
Tablet, film coated, extended releaseOral50 mg/1
Tablet, multilayer, extended releaseOral100 mg
Tablet, multilayer, extended releaseOral50 mg
Tablet, multilayer, extended releaseOral75 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8309060No2012-11-132023-11-20Us
US8114383No2012-02-142024-10-10Us
US6071970No2000-06-062017-06-06Us
US7994364No2011-08-092025-06-27Us
USRE39593No2007-04-242022-08-05Us
US8075872No2011-12-132023-11-20Us
US8536130No2013-09-172028-09-22Us
US8420056No2013-04-162023-11-20Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.87 FDA label
pKa9.34 - 10.45 FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.78 mg/mLALOGPS
logP3.47ALOGPS
logP2.96ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)10.28ChemAxon
pKa (Strongest Basic)9.6ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity69.56 m3·mol-1ChemAxon
Polarizability26.58 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9937
Blood Brain Barrier+0.9232
Caco-2 permeable+0.7912
P-glycoprotein substrateSubstrate0.559
P-glycoprotein inhibitor INon-inhibitor0.9304
P-glycoprotein inhibitor IINon-inhibitor0.9408
Renal organic cation transporterNon-inhibitor0.6918
CYP450 2C9 substrateNon-substrate0.8085
CYP450 2D6 substrateNon-substrate0.5219
CYP450 3A4 substrateSubstrate0.5509
CYP450 1A2 substrateInhibitor0.6665
CYP450 2C9 inhibitorNon-inhibitor0.8856
CYP450 2D6 inhibitorNon-inhibitor0.5538
CYP450 2C19 inhibitorNon-inhibitor0.921
CYP450 3A4 inhibitorNon-inhibitor0.8389
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8875
Ames testNon AMES toxic0.6862
CarcinogenicityNon-carcinogens0.5177
BiodegradationNot ready biodegradable0.9421
Rat acute toxicity2.6035 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7187
hERG inhibition (predictor II)Inhibitor0.6155
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylpropanes
Direct Parent
Phenylpropanes
Alternative Parents
Aralkylamines / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Trialkylamines / Organopnictogen compounds / Organooxygen compounds / Hydrocarbon derivatives
Substituents
Phenylpropane / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Phenol / Tertiary aliphatic amine / Tertiary amine / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Details
1. Mu-type opioid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Tzschentke TM, Christoph T, Kogel B, Schiene K, Hennies HH, Englberger W, Haurand M, Jahnel U, Cremers TI, Friderichs E, De Vry J: (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007 Oct;323(1):265-76. Epub 2007 Jul 26. [PubMed:17656655]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, Hertrampf T, Kogel B, Schiene K, Strassburger W, Terlinden R, Tzschentke TM: Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother. 2012 Jul;13(10):1437-49. doi: 10.1517/14656566.2012.696097. Epub 2012 Jun 15. [PubMed:22698264]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Kneip C, Terlinden R, Beier H, Chen G: Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75. [PubMed:19356073]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Kneip C, Terlinden R, Beier H, Chen G: Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75. [PubMed:19356073]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Kneip C, Terlinden R, Beier H, Chen G: Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75. [PubMed:19356073]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Kneip C, Terlinden R, Beier H, Chen G: Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75. [PubMed:19356073]
  2. Tapentadol FDA Label [File]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Kneip C, Terlinden R, Beier H, Chen G: Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75. [PubMed:19356073]

Drug created on March 19, 2008 10:17 / Updated on December 14, 2018 17:10